| アブストラクト | Epidiolex, the first FDA-approved drug with cannabis extract, treats Dravet and Lennox-Gastaut syndromes. Using data from the FAERS database between 2018 and 2023, this study analyzed 13,275 Epidiolex-related adverse events. Through computational methods (ROR, PRR, BCPNN, EBGM), we found that real-world adverse reactions largely align with those in Epidiolex's drug leaflet. However, Seizure cluster, Blood ketone body decrease, Cortical visual impairment, Hyperactive pharyngeal reflex, and Poverty of speech emerged as potential new side effects not previously listed, warranting further attention for drug safety. |
|---|
| ジャーナル名 | Asian journal of psychiatry |
|---|
| Pubmed追加日 | 2023/11/11 |
|---|
| 投稿者 | Zhou, Qin; Du, Zhiqiang; Qu, Kankan; Shen, Yuan; Jiang, Ying; Zhu, Haohao; Zhang, Xiuhong |
|---|
| 組織名 | Mental Health Center of Jiangnan University, Wuxi Central Rehabilitation;Hospital, Wuxi, Jiangsu 214151, China.;Hospital, Wuxi, Jiangsu 214151, China. Electronic address:;jiangying1010@jiangnan.edu.cn.;Hospital, Wuxi, Jiangsu 214151, China. Electronic address: zhuhh@jiangnan.edu.cn.;Department of Pharmacy, The Affiliated Wuxi People's Hospital of Nanjing Medical;University, Wuxi Medical Center, Nanjing Medical University, Wuxi, Jiangsu,;China. Electronic address: wxzhxh@njmu.edu.cn. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37949044/ |
|---|
